JP2017529852A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017529852A5 JP2017529852A5 JP2017516368A JP2017516368A JP2017529852A5 JP 2017529852 A5 JP2017529852 A5 JP 2017529852A5 JP 2017516368 A JP2017516368 A JP 2017516368A JP 2017516368 A JP2017516368 A JP 2017516368A JP 2017529852 A5 JP2017529852 A5 JP 2017529852A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- patient
- respond
- egfr
- expression level
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 238000000034 method Methods 0.000 claims 17
- 229940121647 egfr inhibitor Drugs 0.000 claims 11
- 206010028980 Neoplasm Diseases 0.000 claims 9
- 201000011510 cancer Diseases 0.000 claims 7
- 108091070395 Homo sapiens miR-31 stem-loop Proteins 0.000 claims 5
- 108091070501 miRNA Proteins 0.000 claims 5
- 239000002679 microRNA Substances 0.000 claims 5
- 102000001301 EGF receptor Human genes 0.000 claims 4
- 108060006698 EGF receptor Proteins 0.000 claims 4
- 239000013610 patient sample Substances 0.000 claims 3
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 2
- 206010009944 Colon cancer Diseases 0.000 claims 2
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims 2
- 239000003153 chemical reaction reagent Substances 0.000 claims 2
- 230000002596 correlated effect Effects 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 239000003112 inhibitor Substances 0.000 claims 2
- 239000000523 sample Substances 0.000 claims 2
- 229940124597 therapeutic agent Drugs 0.000 claims 2
- 206010005003 Bladder cancer Diseases 0.000 claims 1
- 208000003174 Brain Neoplasms Diseases 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 206010052358 Colorectal cancer metastatic Diseases 0.000 claims 1
- 206010014733 Endometrial cancer Diseases 0.000 claims 1
- 206010014759 Endometrial neoplasm Diseases 0.000 claims 1
- 208000008839 Kidney Neoplasms Diseases 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 208000001894 Nasopharyngeal Neoplasms Diseases 0.000 claims 1
- 206010061306 Nasopharyngeal cancer Diseases 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 1
- 206010038389 Renal cancer Diseases 0.000 claims 1
- 208000024770 Thyroid neoplasm Diseases 0.000 claims 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims 1
- 238000001574 biopsy Methods 0.000 claims 1
- 229960005395 cetuximab Drugs 0.000 claims 1
- 201000010536 head and neck cancer Diseases 0.000 claims 1
- 208000014829 head and neck neoplasm Diseases 0.000 claims 1
- 238000000338 in vitro Methods 0.000 claims 1
- 201000010982 kidney cancer Diseases 0.000 claims 1
- 201000007270 liver cancer Diseases 0.000 claims 1
- 208000014018 liver neoplasm Diseases 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 1
- 229960001972 panitumumab Drugs 0.000 claims 1
- 238000004393 prognosis Methods 0.000 claims 1
- 238000002271 resection Methods 0.000 claims 1
- 238000003757 reverse transcription PCR Methods 0.000 claims 1
- 201000002510 thyroid cancer Diseases 0.000 claims 1
- 210000001519 tissue Anatomy 0.000 claims 1
- 201000005112 urinary bladder cancer Diseases 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP14306490.5 | 2014-09-26 | ||
| EP14306490.5A EP3000895A1 (en) | 2014-09-26 | 2014-09-26 | A method for predicting responsiveness to a treatment with an EGFR inhibitor |
| PCT/EP2015/072095 WO2016046365A1 (en) | 2014-09-26 | 2015-09-25 | A method for predicting responsiveness to a treatment with an egfr inhibitor |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2017529852A JP2017529852A (ja) | 2017-10-12 |
| JP2017529852A5 true JP2017529852A5 (enExample) | 2018-10-25 |
Family
ID=51663116
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017516368A Withdrawn JP2017529852A (ja) | 2014-09-26 | 2015-09-25 | Ｅｇｆｒ阻害剤による治療に対する応答性を予測するための方法 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20170298442A1 (enExample) |
| EP (2) | EP3000895A1 (enExample) |
| JP (1) | JP2017529852A (enExample) |
| KR (1) | KR20170086469A (enExample) |
| CN (1) | CN107075583A (enExample) |
| AU (1) | AU2015323744A1 (enExample) |
| BR (1) | BR112017005421A2 (enExample) |
| CA (1) | CA2961434A1 (enExample) |
| MX (1) | MX2017003832A (enExample) |
| WO (1) | WO2016046365A1 (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2976577C (en) | 2015-02-11 | 2024-11-19 | Univ Aarhus | MICRORNA-BASED METHOD FOR THE EARLY DETECTION OF PROSTATE CANCER IN URINE SAMPLES |
| WO2016134727A1 (en) * | 2015-02-27 | 2016-09-01 | Exiqon A/S | A microrna-based method for assessing the prognosis of a prostate cancer patient |
| CN108034727B (zh) * | 2018-01-18 | 2021-05-28 | 四川大学华西医院 | 检测MicroRNA-31-5p表达水平的试剂在制备肿瘤靶向药敏感性检测试剂盒中的用途 |
| KR102480430B1 (ko) * | 2020-10-21 | 2022-12-21 | 순천향대학교 산학협력단 | 주사증 진단을 위한 마이크로RNA-31-5p 및 이의 용도 |
| CN119303090B (zh) * | 2024-10-15 | 2025-06-20 | 中国医学科学院北京协和医院 | miR-210-3p和/或miR-31-5p在薄型子宫内膜中的应用 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2439402A1 (en) | 2001-03-02 | 2002-09-12 | University Of Pittsburgh Of The Commonwealth System Of Higher Education | Pcr method |
| WO2009080437A1 (en) | 2007-12-21 | 2009-07-02 | Exiqon A/S | Micro-rna based drug resistance analysis method |
| US20120095030A1 (en) | 2009-04-17 | 2012-04-19 | The Translational Genomics Research Institute | Methods and kits to predict therapeutic outcome of tyrosine kinase inhibitors |
| SG176773A1 (en) * | 2009-06-19 | 2012-01-30 | Merck Patent Gmbh | Biomarkers and methods for determining efficacy of anti-egfr antibodies in cancer therapy |
| US9598734B2 (en) | 2010-04-29 | 2017-03-21 | Medical Prognosis Institute A/S | Methods and devices for predicting treatment efficacy |
| CA2856594A1 (en) | 2011-11-25 | 2013-05-30 | Integragen | A method for predicting responsiveness to a treatment with an egfr inhibitor |
| CN104046679B (zh) * | 2013-03-11 | 2016-08-24 | 戴勇 | 原发性IgA肾病肾脏组织差异表达miRNA的分析方法和应用 |
-
2014
- 2014-09-26 EP EP14306490.5A patent/EP3000895A1/en not_active Withdrawn
-
2015
- 2015-09-25 US US15/513,223 patent/US20170298442A1/en not_active Abandoned
- 2015-09-25 CN CN201580051832.9A patent/CN107075583A/zh active Pending
- 2015-09-25 MX MX2017003832A patent/MX2017003832A/es unknown
- 2015-09-25 KR KR1020177009944A patent/KR20170086469A/ko not_active Withdrawn
- 2015-09-25 AU AU2015323744A patent/AU2015323744A1/en not_active Abandoned
- 2015-09-25 CA CA2961434A patent/CA2961434A1/en not_active Abandoned
- 2015-09-25 WO PCT/EP2015/072095 patent/WO2016046365A1/en not_active Ceased
- 2015-09-25 BR BR112017005421A patent/BR112017005421A2/pt not_active IP Right Cessation
- 2015-09-25 JP JP2017516368A patent/JP2017529852A/ja not_active Withdrawn
- 2015-09-25 EP EP15767530.7A patent/EP3198028B1/en not_active Not-in-force
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2014533960A5 (enExample) | ||
| Lipsyc et al. | Impact of somatic mutations on patterns of metastasis in colorectal cancer | |
| Bossi et al. | Prognostic and predictive factors in recurrent and/or metastatic head and neck squamous cell carcinoma: a review of the literature | |
| Wang et al. | RETRACTED: Long non-coding RNA HULC promotes bladder cancer cells proliferation but inhibits apoptosis via regulation of ZIC2 and PI3K/AKT signaling pathway | |
| JP2017529852A5 (enExample) | ||
| MX2023001945A (es) | Composiciones y metodos para el cribado de tumores solidos. | |
| Marino et al. | Prognostic significance of miR-34a in Ewing sarcoma is associated with cyclin D1 and ki-67 expression | |
| RU2014110228A (ru) | Диагностические маркеры | |
| MX2019000091A (es) | Metodo para el pronostico y tratamiento de cancer metastasico de los huesos originado de cancer de mama. | |
| JP2015505959A5 (enExample) | ||
| RU2014114617A (ru) | Комбинированные виды лечения, содержащие антагонисты с-мет и антагонисты b-raf | |
| WO2014184679A3 (en) | Method for the prognosis and treatment of renal cell carcinoma metastasis | |
| JP6489658B2 (ja) | 肝細胞癌において分子標的治療の感受性を増加させるための分析方法 | |
| Zhou et al. | Long noncoding RNA ZFAS1 promotes hepatocellular carcinoma proliferation by epigenetically repressing miR-193a-3p. | |
| Tini et al. | The combined EGFR protein expression analysis refines the prognostic value of the MGMT promoter methylation status in glioblastoma | |
| Sproll et al. | Minimal residual disease in head and neck cancer and esophageal cancer | |
| Karagiannis et al. | IGF-IEc expression is associated with advanced differentiated thyroid cancer | |
| Loeschke et al. | Prognostic value of HMGA2, P16, and HPV in oral squamous cell carcinomas | |
| JP2011527575A5 (enExample) | ||
| KR102241063B1 (ko) | 예측성 바이오마커에 대한 검정법 | |
| KR20170086469A (ko) | Egfr 억제제를 사용한 치료에 대한 반응을 예측하는 방법 | |
| Bai et al. | Association between downexpression of miR-1301 and poor prognosis in patients with glioma | |
| Liefaard et al. | RNA signatures from tumor-educated platelets (TEP) enable detection of early-stage breast cancer | |
| Ilie et al. | BRAFV600E mutation analysis by immunohistochemistry in patients with thoracic metastases from colorectal cancer | |
| Gonzalez et al. | Prognostic value of combined p53 and survivin in pT1G3 urothelial carcinoma of the bladder |